July - September 2022
- Total revenue
SEK 3,999 M (3,761), +6 per cent, -6 per cent at constant exchange rates (CER)1 - Haematology revenue
SEK 2,619 M (2,291), +3 per cent at CER of which Elocta®SEK 1,041 M (1,035), -5 per cent at CER; Alprolix®SEK 464 M (430), +2 per cent at CER; Doptelet®SEK 543 M (400), +12 per cent at CER and Aspaveli®/Empaveli™SEK 49 M (-) - Immunology revenue
SEK 1,070 M (1,144), -22 per cent at CER of which Kineret®SEK 542 M (516), -10 per cent at CER; Synagis®SEK 327 M (374), -30 per cent at CER and Gamifant®SEK 202 M (255), -36 per cent at CER - EBITA
1 SEK 1,241 M (1,166); EBITA margin1 31 percent (31) . EBITSEK 699 M (708) - Earnings per share (EPS) before dilution
SEK 1.52 (1.60). Cash flow from operating activitiesSEK 780 M (257)
January - September 2022
- Total revenue
SEK 12,800 M (10,633), +20 per cent, +9 per cent at CER - Haematology revenue
SEK 7,806 M (6,294), +14 per cent at CER of which EloctaSEK 3,173 M (2,896), +5 per cent at CER; AlprolixSEK 1,351 M (1,281), stable at CER; DopteletSEK 1,754 M (810), +85 per cent at CER and Aspaveli/EmpaveliSEK 91 M (-) - Immunology revenue
SEK 4,036 M (3,450), +3 per cent at CER of which KineretSEK 1,731 M (1,608), -4 per cent at CER; SynagisSEK 1,652 M (1,286), +12 per cent at CER and GamifantSEK 653 M (556), stable at CER - EBITA
SEK 3,475 M (3,572); EBITA margin 27 percent (34) including items affecting comparability (IAC)2 ofSEK -675 M. Excluding IAC EBITA adjusted1 wasSEK 4,150 M corresponding to an EBITA margin adjusted1 of 32 percent (34) . EBITSEK 1,897 M (2,208); EBIT adjusted1 SEK 2,572 M (2,208) - EPS before dilution
SEK 4.24 (4.87), EPS adjusted1 before dilutionSEK 6.08 (4.87). Cash flow from operating activitiesSEK 2,767 M (3,349)
2022 outlook unchanged
Financial summary
Investors, analysts and media are invited to participate in a conference call which will include a presentation of the results and a Q&A session at
The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com prior to the conference call.
To participate in the conference call, please call:
US: +1 646 722 4957
Sobi®
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Providing sustainable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at
Head of Communication and Investor Relations
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-publishes-q3-2022-report,c3655802
https://mb.cision.com/Main/14266/3655802/1644140.pdf
https://news.cision.com/swedish-orphan-biovitrum-ab/i/3655802-0-png,c3106424
(c) 2022 Cision. All rights reserved., source